Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Armata Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $54.9M

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income54.9-26.7
EPS (diluted, $ a share)$-0.24$-0.74

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: ARMP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Armata Pharmaceuticals, Inc.: key numbers

Share price
$2.99Close, Nov 16
Market cap
$111M
Shares outstanding
37.19MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Armata Pharmaceuticals, Inc.

All →
4:24 PM ET 8-K
Financial Results

Armata Pharmaceuticals Financial Results

Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”

Dr. Deborah Birx, Chief Executive Officer

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”

Dr. Deborah Birx, Chief Executive Officer
7:11 AM ET 8-K
Business Update

Armata Pharmaceuticals Business Update

Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its AP-SA02 bacteriophage candidate. This incremental funding brings the total cumulative government support for the program to $32.4 million and is intended to fund activities for a pivotal superiority study in complicated S. aureus bacteremia.

Counterparty
U.S. Department of War
7:12 AM ET 8-K
Regulatory Approval

Armata Pharmaceuticals Regulatory Approval

Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 product candidate for the treatment of complicated S. aureus bacteremia. The designation is supported by Phase 2 data showing a 100% clinical response rate without relapse at 28 days, compared to 75% for the placebo group. This status is intended to expedite the development and review of the therapy, which could potentially become the first antibacterial treatment approved based on superiority to current standard-of-care.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.